# Curie.Bio

> Curie.Bio is a VC fund backing Biotechnology and Therapeutics. See 12 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Total investments: 12
- Last investment: Mar 2026
- Lead investor: 50%
- Last updated: Aug 2026
- Website: https://curie.bio/

Curie.Bio is a founder-focused seed-stage venture capital firm.

## Contacts

5 contacts available for Curie.Bio. Shizune tracks 4 team members at Curie.Bio. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/curie-bio?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 9 | 75% |
| Therapeutics | 6 | 50% |
| Health Care | 5 | 42% |
| Medical | 2 | 17% |
| Fitness | 1 | 8% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Seed | 11 | 92% |
| Series A | 1 | 8% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 7 | 58% |
| United Kingdom | 2 | 17% |
| Australia | 1 | 8% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Alexis Borisy | Co-Founder & Chairman | 14 | https://shizune.co/investors/profile/alexis-borisy |
| Zach Weinberg | Co-Founder and CEO | 73 | https://shizune.co/investors/profile/zach-weinberg |
| Ben Auspitz | Managing Partner, Breakout Fund | 11 | https://shizune.co/investors/profile/ben-auspitz |
| Christoph Lengauer | Co-Founder and CSO | 0 | https://shizune.co/investors/profile/christoph-lengauer |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| R1 Therapeutics | R1 Therapeutics is a clinical‑stage biopharmaceutical company focused on discovering and developing new drug therapies for patients with kidney disease. The company’s primary work centers on advancing AP306, a therapeutic candidate designed to treat hyperphosphatemia—a condition of elevated phosphate levels that commonly affects individuals withchronic kidney disease on dialysis—by blocking key active phosphate transport pathways in the gut. In its operations, R1 Therapeutics works on progressing AP306 through mid- and late-stage clinical studies and aims to bring an alternative treatment option to patients struggling with phosphate management complications associated with chronic kidney disease. | $77.5M | Series A | Mar 17, 2026 |  |
| Stealth Mode Biotech | Drug Discovery |  | Seed | Dec 20, 2024 |  |
| Alkira Bio | Alkira Bio utilizes its proprietary LASEREDD® technology platform to discover therapeutic antibodies that target complex membrane proteins previously considered inaccessible, thereby advancing drug discovery into new frontiers. |  | Seed | Jul 04, 2024 |  |
| Tesseract Medical Research | Tesseract Medical Research is a biotechnology and medical sciences business focused on delivering nutrition to meet unmet needs. | $20M | Seed | Jun 11, 2024 |  |
| Remunix | Developing antibody-based therapies for autoimmune diseases by targeting immune cell activation and checkpoints. |  | Seed | Feb 28, 2024 |  |
| Osteologic Therapeutics | Biotechnology company harnessing the skeleton to create transformative biologic medicines. |  | Seed | Nov 22, 2023 |  |
| FunctionRx | FunctionRx is a biotechnology company developing therapies for neurodegeneration. |  | Seed | Nov 21, 2023 |  |
| Rhino Therapeutics, Inc. | Pioneering olfactory loss therapies, focused on age-related olfactory loss (presbyosmia). |  | Seed | Jul 24, 2023 |  |
| Cell Control Biotherapeutics | Cell Control Bio is a biotechnology company that develops in vivo CAR-T therapies and cell engineering platforms. |  | Seed | Dec 24, 2022 |  |
| Decrypt Biomedicine | Decrypt Biomedicine develops small molecule drugs that hit cryptic binding sites on validated but difficult-to-drug protein targets. |  | Seed | Dec 01, 2022 |  |

10 of 12 investments shown.

## Co-investors
- [Abingworth](https://shizune.co/investors/profile/abingworth-management) — VC Fund, 1 deal together
- [Caffeinated Capital](https://shizune.co/investors/profile/caffeinated-capital) — VC Fund, 1 deal together
- [Chengwei Capital](https://shizune.co/investors/profile/chengwei-capital) — VC Fund, 1 deal together
- [DaVita Venture Group](https://shizune.co/investors/profile/davita-venture-group) — VC Fund, 1 deal together
- [F-Prime](https://shizune.co/investors/profile/f-prime-capital-partners) — VC Fund, 1 deal together
- [Geding Ventures](https://shizune.co/investors/profile/geding-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund

### Similar country
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Artesian VC](https://shizune.co/investors/profile/artesian-capital-management) — VC Fund
- [Blackbird Ventures](https://shizune.co/investors/profile/blackbird-ventures-australia) — VC Fund

## Featured in investor lists
- [Biotech VC Funds in Oceania](https://shizune.co/investors/biotech-vc-funds-oceania)
- [Biotechnology Investors in Australia](https://shizune.co/investors/biotechnology-investors-australia)
- [Biotechnology VC Funds in Australia](https://shizune.co/investors/biotechnology-vc-funds-australia)
- [Biotech Investors in Australia](https://shizune.co/investors/biotech-investors-australia)
- [Biotech VC Funds in Australia](https://shizune.co/investors/biotech-vc-funds-australia)

## FAQ

### What does Curie.Bio invest in?

Curie.Bio invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Seed and Series A stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Curie.Bio?

Public channels for Curie.Bio include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Curie.Bio?

The team at Curie.Bio includes Alexis Borisy (Co-Founder & Chairman), Zach Weinberg (Co-Founder and CEO) and Ben Auspitz (Managing Partner, Breakout Fund). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co